Novartis License Agreement was Monte Rosa Therapeutics’s largest revenue line in fiscal 2024, bringing in $41.60M of $75.60M (55%).
| Agreement | FY 2024 |
|---|---|
| Novartis License Agreement | $41.60M |
| Collaboration & License Agreement | $34.00M |
| Total | $75.60M |
Monte Rosa Therapeutics brought in $75.60M from its two revenue lines in fiscal 2024, the year ended December 31, 2024. Novartis License Agreement was the largest at $41.60M (55.0%), ahead of Collaboration & License Agreement at $34.00M (45.0%).
Monte Rosa Therapeutics (GLUE) reports its revenue by agreement. In fiscal 2024, Novartis License Agreement was its largest revenue line, bringing in $41.60M (55.0% of the total), followed by Collaboration & License Agreement at $34.00M (45.0%).
Novartis License Agreement was Monte Rosa Therapeutics' largest revenue line in fiscal 2024, bringing in $41.60M, or 55.0% of the $75.60M total across its two revenue lines.
Every figure comes from Monte Rosa Therapeutics' annual financial filings, as reported. Each line keeps the name Monte Rosa Therapeutics gives it, and years follow its fiscal calendar.
Monte Rosa Therapeutics' revenue by agreement goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.